Which of the following is a leukotriene receptor antagonist?

Which of the following is a leukotriene receptor antagonist?

• A. Theophylline
• B. Montelukast
• C. Cromolyn
• D. Albuterol

Answer: (B)

Montelukast is classified as a leukotriene receptor antagonist, which means it works by inhibiting the action of leukotrienes. These are inflammatory chemicals the body releases during an asthma attack, contributing to airway inflammation, bronchoconstriction, and mucus production. By blocking leukotriene receptors, Montelukast effectively reduces the inflammation and constriction in the airways, helping to improve breathing and control asthma symptoms. Theophylline, although it is an asthma medication, primarily works as a bronchodilator by relaxing the muscles around the airways. Cromolyn is a mast cell stabilizer that prevents the release of histamine and other inflammatory mediators but does not act on leukotriene receptors. Albuterol is a short-acting beta-agonist that acts as a bronchodilator to relieve immediate asthma symptoms but does not target leukotriene pathways. Therefore, Montelukast is specifically recognized for its role as a leukotriene receptor antagonist in asthma management.

Montelukast is classified as a leukotriene receptor antagonist, which means it works by inhibiting the action of leukotrienes. These are inflammatory chemicals the body releases during an asthma attack, contributing to airway inflammation, bronchoconstriction, and mucus production. By blocking leukotriene receptors, Montelukast effectively reduces the inflammation and constriction in the airways, helping to improve breathing and control asthma symptoms.

Theophylline, although it is an asthma medication, primarily works as a bronchodilator by relaxing the muscles around the airways. Cromolyn is a mast cell stabilizer that prevents the release of histamine and other inflammatory mediators but does not act on leukotriene receptors. Albuterol is a short-acting beta-agonist that acts as a bronchodilator to relieve immediate asthma symptoms but does not target leukotriene pathways. Therefore, Montelukast is specifically recognized for its role as a leukotriene receptor antagonist in asthma management.